These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16328539)

  • 1. Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter.
    Cachat F; Bardy D; Durussel C; Di Paolo E
    Pediatr Nephrol; 2006 Feb; 21(2):301-2. PubMed ID: 16328539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteplase as hemodialysis catheter locking solution and spurious hyperphosphatemia.
    Sombolos K; Bamichas G; Hatsiou V; Fragidis S; Rizos A; Natse T; Fytili C
    J Vasc Access; 2011; 12(3):269. PubMed ID: 21218384
    [No Abstract]   [Full Text] [Related]  

  • 3. Spurious hyperphosphatemia in patients on hemodialysis with catheters.
    Schiller B; Virk B; Blair M; Wong A; Moran J
    Am J Kidney Dis; 2008 Sep; 52(3):617-20. PubMed ID: 18534730
    [No Abstract]   [Full Text] [Related]  

  • 4. Alteplase versus urokinase for occluded hemodialysis catheters.
    Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
    Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial.
    Gittins NS; Hunter-Blair YL; Matthews JN; Coulthard MG
    Arch Dis Child; 2007 Jun; 92(6):499-501. PubMed ID: 17068072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteplase infusion versus dwell for clearance of partially occluded central venous catheters in critically ill pediatric patients.
    Ragsdale CE; Oliver MR; Thompson AJ; Evans MC
    Pediatr Crit Care Med; 2014 Jul; 15(6):e253-60. PubMed ID: 24751787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective use of alteplase for occluded tunneled venous catheter in hemodialysis patients.
    Mendes ML; Castro JH; Silva TN; Barretti P; Ponce D
    Artif Organs; 2014 May; 38(5):399-403. PubMed ID: 24117542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tackling the Achilles' heel of hemodialysis.
    Winkelmayer WC
    N Engl J Med; 2011 Jan; 364(4):372-4. PubMed ID: 21268730
    [No Abstract]   [Full Text] [Related]  

  • 9. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices.
    Timoney JP; Malkin MG; Leone DM; Groeger JS; Heaney ML; Keefe DL; Klang M; Lucarelli CD; Muller RJ; Eng SL; Connor M; Small TN; Brown AE; Saltz LB
    J Clin Oncol; 2002 Apr; 20(7):1918-22. PubMed ID: 11919252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study).
    Blaney M; Shen V; Kerner JA; Jacobs BR; Gray S; Armfield J; Semba CP;
    J Vasc Interv Radiol; 2006 Nov; 17(11 Pt 1):1745-51. PubMed ID: 17142704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteplase for blood flow restoration in hemodialysis catheters: a multicenter, randomized, prospective study comparing "dwell" versus "push" administration.
    Vercaigne LM; Zacharias J; Bernstein KN
    Clin Nephrol; 2012 Oct; 78(4):287-96. PubMed ID: 22541682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spurious Hyperphosphatemia in a Patient with Chronic Kidney Disease - a Rare Case of Alteplase Contamination.
    Khan ZUN; Ahmed S; Siddiqui A; Siddiqui I
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spurious Hyperphosphatemia in Two Children With End-Stage Renal Disease: A Case Report.
    Ahmed FS; Begum M; AlSharhan MA
    Cureus; 2024 Mar; 16(3):e55818. PubMed ID: 38590456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteplase for the treatment of catheter occlusion in pediatric patients.
    Anderson DM; Pesaturo KA; Casavant J; Ramsey EZ
    Ann Pharmacother; 2013 Mar; 47(3):405-9. PubMed ID: 23463740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of tissue plasminogen activator in catheters used for extracorporeal renal replacement therapy.
    Langston C; Eatroff A; Poeppel K
    J Vet Intern Med; 2014; 28(2):270-6. PubMed ID: 24438008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteplase use for malfunctioning central venous catheters correlates with catheter-associated bloodstream infections.
    Rowan CM; Miller KE; Beardsley AL; Ahmed SS; Rojas LA; Hedlund TL; Speicher RH; Nitu ME
    Pediatr Crit Care Med; 2013 Mar; 14(3):306-9. PubMed ID: 23392362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteplase for the management of occluded central venous access devices: safety considerations.
    Smith LH
    Clin J Oncol Nurs; 2008 Feb; 12(1):155-7. PubMed ID: 18258586
    [No Abstract]   [Full Text] [Related]  

  • 18. Urokinase: new indication. Thrombosed venous and dialysis catheters: when heparin fails. Urokinase clears about 75% of thrombosed venous catheters intended for long-term use with a dose-related increase in the bleeding risk.
    Prescrire Int; 2009 Jun; 18(101):118. PubMed ID: 19637430
    [No Abstract]   [Full Text] [Related]  

  • 19. A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction.
    Little MA; Walshe JJ
    Am J Kidney Dis; 2002 Jan; 39(1):86-91. PubMed ID: 11774106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of an alteplase algorithm for the management of hemodialysis catheter dysfunction.
    Abdelmoneim AS; Miller LM; Armstrong S; Sood MM; Wazny L; Chateau D; Vercaigne LM
    Hemodial Int; 2012 Apr; 16(2):298-305. PubMed ID: 22098698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.